Category: Research & Development
St. Jude Medical enrolls the 1st patient in a clinical trial of its next-generation Quadra Assura MP multi-point cardiac pacing system in patients with heart failure.
St. Jude Medical (NYSE:STJ) enrolled the 1st patient in a clinical study evaluating pacing in multiple points on the heart, the company announced today.
Medical device maker Insulet teams up with pharmaceutical giant Eli Lilly in development of an insulin pump designed for patients with a highly insulin resistant form of diabetes.
Abiomed's Impella heart pumps improve patients' quality of life and costs well below the national standard for cost-effective therapies, according to the company.
Heart support technologies maker Abiomed (NSDQ:ABMD) announced that its Impella heart pump cheaply and effectively improved patients' quality of life, costing less than $39,500 per quality-of-life-year (QALY) gained for high-risk heart failure patients.
Medtronic and China's National Institute of Hospital Administration team up to develop treatment pathways for patients with Type I diabetes.
Medical device industry titan Medtronic (NYSE:MDT) launched a new partnership with Chinese national healthcare regulators to gather data and inform a national program of care for patients with Type I diabetes.
InspireMD gets a Wall Street boost after announcing FDA approval to begin a U.S. clinical trial of its MGuard Embolic Protection Stent.
Stent technology maker InspireMD (OTC:NSPR) gained a few points on Wall Street today on news that the FDA gave the company a conditional green light to proceed with a clinical trial of its MGuard Embolic Protection Stent.
Medical device company Medtronic signed up to provide a heart rhythm monitoring and assessment component to a clinical study assessing ARCA biopharma's genetically targeted cardiovascular drug therapy.
Medical device industry heavy-weight Medtronic (NYSE:MDT) entered a collaboration agreement with ARCA biopharma, providing continuous cardiac monitoring of patients undergoing experimental treatment with a genetically targeted cardiovascular drug therapy.
Cook Medical launches a clinical study of its Zilver Vena stent, the 1st trial of its kind in the U.S. assessing an iliofemoral venous self-expanding stent.
Indiana medical device giant Cook Medical announced the launch of a new clinical study, the 1st of its kind evaluating the safety and effectiveness of its Zilver Vena venous self-expanding stent.
The VIVO study will enroll select adult patients experiencing limiting leg pain, leg swelling or skin discoloration or a healed or active lower leg ulcer, according to a Cook statement.
